They just updated their tracker with information about new opioid labeling, forthcoming dietary guidelines, autism announcements, and more
To be clear, this isn't about anyone in particular but a collection of things Ive seen recently
Seventy participants (mean (s.d.) age = 47.3 (10.3) years, 58 (82.9%) female and 12 (17.1%) male) were randomized to receive 2.4 mg semaglutide ( n = 35) or placebo ( n = 35)
Because those components move independently, two patients on the "same" program can pay very different amounts
Additionally, there is conflicting evidence in the literature concerning whether Semaglutide causes an inordinate amount of lean mass loss compared to situations where the same amount of weight is lost without the use of Semaglutide
However, FDA inspections have identified quality control concerns, and the parent company has a documented history of regulatory issues